PLoS Medicine Study Compares Effectiveness of NVP in Women Previously Exposed to Drug
February 19, 2010
"Intrapartum and neonatal single-dose nevirapine (NVP) reduces the risk of mother-to-child HIV transmission but also induces viral resistance to non-nucleoside reverse transcriptase inhibitor (NNRTI) drugs," write the authors of a PLoS Medicine study that compares the effectiveness of the drug in women who had previously been exposed to the drug to those who had not. The authors conclude, "Single-dose intrapartum and neonatal NVP is among the simplest and most feasible interventions available and remains a cornerstone of perinatal HIV prevention in many under-resourced settings ... [W]hen used judiciously in conjunction with ART for women eligible for treatment, single-dose NVP to prevent mother-to-child HIV transmission can be administered without substantially comprising the mother's future antiretroviral treatment options" (Stringer et al., 2/16).
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.